**Acknowledgement**

The views expressed in this manuscript are those of the authors and do not reflect the official policy or position of the Department of the Army, Department of Air Force, Department of Defense, or the U. S. Government.

The Use of rLH, HMG and hCG in Controlled Ovarian Stimulation for Assisted Reproductive Technologies 67

[11] Bruysters M, Christin-Maitre S, Verhoef-Post M, Sultan C, Auger J, Faugeron I, et al. A new LH receptor splice mutation responsible for male hypogonadism with subnormal sperm production in the propositus, and infertility with regular cycles in an affected

[12] Gromoll J, Schulz A, Borta H, Gudermann T, Teerds KJ, Greschniok A, et al. Homozygous mutation within the conserved Ala-Phe-Asn-Glu-Thr motif of exon 7 of the LH receptor causes male pseudohermaphroditism. European Journal of

[13] Huhtaniemi IT. LH and FSH receptor mutations and their effects on puberty. Hormone

[14] Lahoud R, Al-Jefout M, Tyler J, Ryan J, Driscoll G. A relative reduction in mid-follicular LH concentrations during GnRH agonist IVF/ICSI cycles leads to lower live birth rates.

[15] O'Dea L, O'Brien F, Currie K, Hemsey G. Follicular development induced by recombinant luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in anovulatory women with LH and FSH deficiency: evidence of a threshold effect.

[16] Shoham Z, Smith H, Yeko T, O'Brien F, Hemsey G, O'Dea L. Recombinant LH (lutropin alfa) for the treatment of hypogonadotrophic women with profound LH deficiency: a randomized, double-blind, placebo-controlled, proof-of-efficacy study. Clinical

[17] Schoot DC, Harlin J, Shoham Z, Mannaerts B, Lahlou N, Bouchard P, et al. Recombinant human follicle-stimulating-hormone and ovarian response in gonadotropin-deficient

[18] Lunenfeld B. Historical perspectives in gonadotrophin therapy. Hum Reprod Update.

[19] Howles CM, Loumaye E, Giroud D, Luyet G. Multiple follicular development and ovarian steroidogenesis following subcutaneous administration of a highly purified urinary FSH preparation in pituitary desensitized women undergoing IVF: a multicentre European phase III study. Hum Reprod. Clinical Trial, Clinical Trial, Phase

[20] van de Weijer BH, Mulders JW, Bos ES, Verhaert PD, van den Hooven HW. Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities. Reprod Biomed

[21] Hill MJ, Levy G, Levens ED. Does exogenous LH in ovarian stimulation improve assisted reproduction success? An appraisal of the literature. Reproductive biomedicine

[22] Bosch E, Vidal C, Labarta E, Simon C, Remohi J, Pellicer A. Highly purified hMG versus recombinant FSH in ovarian hyperstimulation with GnRH antagonists--a randomized study. Human reproduction. [Randomized Controlled Trial]. 2008 Oct;23(10):2346-51.

sister. Human Reproduction. 2008 Aug;23(8):1917-23.

Research. [Article; Proceedings Paper]. 2002;57:35-8.

Current Medical Research and Opinion. 2008;24(10):2785-93.

women. Human Reproduction. 1994 Jul;9(7):1237-42.

Historical Article [Review]. 2004 Nov-Dec;10(6):453-67.

III [Multicenter Study]. 1994 Mar;9(3):424-30.

Online. 2003 Nov;7(5):547-57.

online. 2012 Mar;24(3):261-71.

Human Reproduction. 2006 Oct;21(10):2645-9.

Endocrinology. 2008 Sep;69(3):471-8.

Endocrinology. 2002 Nov;147(5):597-608.

This research was supported, in part, by Intramural research program of the Program in Reproductive and Adult Endocrinology, NICHD, NIH.
